Group 1 - The core point of the article is that 嘉和生物-B (06998) has completed a proposed merger and will be renamed "亿腾嘉和医药集团有限公司" starting December 31, 2024 [1] - 嘉和生物's stock price increased by over 7% during trading, with a current price of 3.21 HKD and a trading volume of 2.2008 million HKD [1] - The merger agreement with 亿腾医药 was signed on September 13, 2024, and it marks the first reverse acquisition case in the Hong Kong stock market under the 18A listing rules [1] Group 2 - 嘉和生物 announced that its drug 来罗西利 (GB491) has been included in the national medical insurance drug list, which is expected to significantly enhance patient accessibility and reduce economic burden [1] - The inclusion of 来罗西利 (GB491) in the insurance list is anticipated to accelerate its commercialization process and market penetration, thereby boosting innovative returns for the company [1]
港股异动 | 嘉和生物-B(06998)现涨超4% 建议合并已完成 拟更名为“亿腾嘉和”并移除“B”标记